Front matter

▸# Acute Kidney Injury (ICC-3 093)titleL0001
▸> source: Acute kidney injury 25-26 Mona Roushdy.pdf | 46 slides | converted 2026-09-02metaL0002
Slide 1[L0003]
▸![figure](slide01.png)figure_refL0004

ICC-3 (093)Acute Kidney Injury[L0006–L0026]

▸Mona RoushdynavL0006
▸Professor of Internal Medicine and Nephrology Cairo UniversitymetaL0007
L0008
▸Mona.roshdy@ngu.edu.egmetaL0009
▸Academic year 25-26metaL0010
▸![figure](slide02.png)Slide 2figure_refL0011
Slide 3[L0012]
▸By the end of this session, you should be able to:frameL0013
▸• Understand the various causes leading to acute kidney injuryL0014
L0015
Explain like I'm five
What
Goal: know the range of things that can cause AKI, not just one.
Where
The lecture's own Outline (Slide 4) splits this into prerenal, renal parenchymal and post-renal causes, plus a separate group of other causes — rhabdomyolysis, contrast, tumour lysis.
▸• Analyse the history and describe the clinical findings in patients with AKIL0016
L0017
Explain like I'm five
What
Goal: take a history and pick out the clinical findings in an AKI patient.
Where
Not named in the Outline, but covered later: 'Is it prerenal or renal?' opens with History and Clinical Examination (the rows below), and 'Clinical picture' covers oliguria and ATN's phases (the rows below).
▸• Outline the emergency investigationsL0018
Explain like I'm five
What
Goal: know which investigations are done urgently when AKI is suspected.
Why
She calls these 'emergency' investigations but this slide does not say why they are urgent, or what makes AKI time-critical to investigate.
▸• Differentiate between acute and chronic renal impairment or failureL0019
L0020
Explain like I'm five
What
Goal: tell acute renal impairment/failure apart from chronic renal failure.
How
The 'Acute or chronic uremia?' slide gives five criteria: previous creatinine, the anaemia/PTH/phosphate/calcium pattern, kidney size on ultrasound, symptom chronicity, and oliguria (the rows below).
▸• Explain the management of different causes of AKIL0021
L0022
Explain like I'm five
What
Goal: explain how management differs depending on which cause of AKI is present.
Where
The Slide 4 Outline names 'Management' as its own section, following the three-way causes split — prerenal, renal parenchymal, post-renal — that this goal maps to.
▸• Enumerate the indications of dialysis in AKIL0023
Explain like I'm five
What
Goal: list the reasons AKI would push a patient to dialysis.
Where
Not named in the Outline, but covered later: the 'Renal replacement Therapy' slide lists five indications for dialysis (the rows below).
▸• Appreciate the importance of prompt action to reverse AKIL0024
L0025
Explain like I'm five
What
Goal: appreciate that acting fast on AKI matters, once it is suspected.
Why
The word 'reverse' frames AKI as something that can be undone if caught early — the reason prompt action is named as its own objective here.
▸![figure](slide03.png)Slide 3figure_refL0026

Outline shown 1 of 6[L0028–L0041]

▸• DefinitionnavL0028
▸• ClassificationnavL0029
▸• EpidemiologynavL0030
▸• Approaching AKI causes:navL0031
▸PrerenalnavL0032
▸Renal parenchymalnavL0033
▸Post renalnavL0034
▸• ManagementnavL0035
▸• OutcomenavL0036
▸• Other causes of AKInavL0037
▸RhabdomyolysisnavL0038
▸Contrast inducednavL0039
▸Acute tumour lysis syndromenavL0040
▸![figure](slide04.png)Slide 4figure_refL0041

Definition[L0043–L0046]

▸• There is an abrupt deterioration in renal function, usually over hours or days.L0043
L0044
Explain like I'm five
What
AKI is a sudden drop in how well the kidneys work.
Where
Kidney function overall, not one named structure inside it.
Why
She marks the change as 'abrupt' but doesn't state why the speed of onset, rather than a slower decline, is what defines it as acute.
When
It develops over hours to days — that speed is what makes it 'acute'.
▸• It is usually (but not always) reversible over days or weeks.exceptionL0045
Explain like I'm five
What
Most of the time, kidney function comes back on its own.
Why
She states it is usually reversible but does not say why some cases are and others are not.
When
Recovery, when it happens, takes days to weeks.
ExceptionStates reversibility is 'usual' and its own exception in one line: usually, but not always, reversible over days to weeks.
▸![figure](slide05.png)Slide 5figure_refL0046
Slide 5 — DefinitionSlide 5 — Definition

Two bullets matching the rows above verbatim. 'hours or days', in the first bullet, is highlighted yellow.

The highlight singles out the timing clause of the definition as the point to remember.

Outline shown 2 of 6[L0048–L0061]

▸• DefinitionnavL0048
▸• ClassificationnavL0049
▸• EpidemiologynavL0050
▸• Approaching AKI causes:navL0051
▸PrerenalnavL0052
▸Renal parenchymalnavL0053
▸Post renalnavL0054
▸• ManagementnavL0055
▸• OutcomenavL0056
▸• Other causes of AKInavL0057
▸RhabdomyolysisnavL0058
▸Contrast inducednavL0059
▸Acute tumour lysis syndromenavL0060
▸![figure](slide06.png)Slide 6figure_refL0061

Classification of kidney injury RIFLE and the network criteria[L0063–L0080]

RIFLE and AKIN, stage by stage

Lines up each RIFLE tier against its AKIN counterpart on the same two measurements so a threshold match or a gap is visible stage by stage.

RIFLE criteria vs AKIN criteria — sCreatinine and urine output — dotted cells are her words from the rows below; solid ones are those rows condensed
CriteriaRIFLEAKIN
Risk / Stage 1 — sCreatinine↑sCrea × 1.5↑ sCrea × 1.5 or ↑≥0.3 mg/dl in sCrea
Risk / Stage 1 — Urine output< 0.5 ml/kg per h × 6 h< 0.5 ml/kg per h × 6 h
Injury / Stage 2 — sCreatinine↑sCrea × 2↑sCrea × 2
Injury / Stage 2 — Urine output< 0.5 ml/kg per h × 12 h< 0.5 ml/kg per h × 12 h
Failure / Stage 3 — sCreatinine↑sCrea × 3 or ≥ 0.5 mg/dl if baseline sCrea ↑ > 4.0 mg/dl↑sCrea × 3 or ↑≥0.5 mg/dl if baseline sCrea > 4.0 mg/dl
Failure / Stage 3 — Urine output< 0.3 ml/kg per h × 24 h or anuria × 12 h< 0.3 ml/kg per h × 24 h or anuria × 12 h
LossComplete loss of renal function > 4 weekssource silent
End-stageEnd-stage renal diseasesource silent
Initiation of renal replacement therapysource silentPatients who receive RRT are considered to have met stage 3 criteria, irrespective of the stage they are in at the time of RRT.
Explain like I'm five
What
Same ruler, same three severity bands, same two measurements — creatinine fold-rise and urine output. AKIN's Stage 1 also fires on a smaller absolute rise; RIFLE alone keeps two tiers past Failure.
Why
The two systems diverge in three places, not two: RIFLE's Loss and End-stage tiers have no AKIN match, and AKIN separately defines Stage 3 by RRT initiation alone (the row below), a rule RIFLE does not carry.

Why this matters: AKIN's Stage 1 also fires on a smaller absolute creatinine rise (≥0.3 mg/dl) than RIFLE's Risk tier states, and RIFLE keeps two tiers past Failure (Loss, End-stage) that AKIN never names — reading a stage number across systems without this table risks under- or over-grading severity.

▸![figure](slide07.png)Slide 7figure_refL0063
RIFLE / AKIN staging criteria diagramRIFLE / AKIN staging criteria diagram

A staged severity chart: RIFLE's five tiers (Risk, Injury, Failure, Loss, End-stage) and AKIN's three tiers (Stage 1, Stage 2, Stage 3) each set against an sCreatinine threshold and a urine-output threshold, arranged least to most severe under an 'Increasing severity' label with an 'Outcome' marker.

The stepped shape ranks the tiers by severity at a glance and shows RIFLE running two tiers past where AKIN stops — a fact no single text line states outright.

▸RIFLE criteriaL0064
Explain like I'm five
What
RIFLE is the name of one system for grading how severe an episode of kidney injury is.
Where
The first of two staging tables on this slide; AKIN, the second, follows further down.
Why
She doesn't state why a formal severity scale is needed or what clinical decisions it is meant to guide.
▸sCreatinineL0065
Explain like I'm five
What
One of RIFLE's two measurements: how much the blood creatinine has risen from baseline.
Why
She doesn't state why a rise in creatinine, rather than its absolute level, is the value tracked.
▸Urine output criteriaL0066
Explain like I'm five
What
RIFLE's other measurement: how little urine the patient is making, per kg of body weight per hour.
Why
She doesn't state why urine output is normalised to body weight rather than measured as a raw volume.
▸Risk: ↑sCrea × 1.5 | < 0.5 ml/kg per h × 6 hL0067
Explain like I'm five
What
RIFLE's mildest tier, Risk, is given as two criteria side by side: creatinine up 1.5-fold; urine output under 0.5 ml/kg/h.
Why
She doesn't state whether the creatinine and urine-output criteria must both be met, or either alone is enough.
When
The urine-output route only counts once that low output has lasted at least 6 hours.
▸Injury: ↑sCrea × 2 | < 0.5 ml/kg per h × 12 hL0068
Explain like I'm five
What
RIFLE's middle tier, Injury, is given as two criteria side by side: creatinine up 2-fold; urine output under 0.5 ml/kg/h.
Why
She doesn't state why the urine-output duration doubles from Risk to Injury while the flow-rate threshold itself stays the same.
When
The urine-output route requires that same low output to persist for at least 12 hours — double Risk's window.
▸Failure: ↑sCrea × 3 or ≥ 0.5 mg/dl if baseline sCrea ↑ > 4.0 mg/dl | < 0.3 ml/kg per h × 24 h or anuria × 12 hL0069
Explain like I'm five
What
RIFLE's Failure tier: creatinine up 3-fold, or a jump of at least 0.5 mg/dl once baseline already exceeds 4.0 mg/dl.
Why
She doesn't state why a smaller absolute rise (0.5 mg/dl) counts once creatinine is already above 4.0 mg/dl.
When
By urine output: under 0.3 ml/kg/h for 24 hours, or complete anuria for as little as 12 hours.
▸Loss: Complete loss of renal function > 4 weeksL0070
Explain like I'm five
What
Loss: kidney function stays completely gone — a separate, worse tier than Failure, not just a bigger number.
Why
She doesn't state why 4 weeks specifically is the line, rather than a shorter or longer window.
When
Counted only once that complete loss has lasted more than 4 weeks.
▸End-stage: End-stage renal diseaseL0071
Explain like I'm five
What
End-stage: end-stage renal disease — RIFLE's final and worst tier.
When
Unlike every other RIFLE tier, no duration or numeric threshold is given for when a case counts as End-stage.
▸Increasing severityL0072
Explain like I'm five
What
Labels the direction of the RIFLE list: each stage further down (Risk toward End-stage) is more severe than the one before it.
RIFLE's tiers are ranked, not just listed

The RIFLE stages are read low to high severity: Risk is mildest, End-stage is worst.

Explain like I'm five
What
The RIFLE table is headed 'Increasing severity', marking the named tiers (Risk through End-stage) as a graded scale rather than a plain list.
Where
This heading sits directly beside the RIFLE criteria table, on the same slide as the creatinine and urine-output columns.

Why this matters: Without the ranking stated, the five names read as a category list rather than a severity scale, which changes what a stage number is supposed to communicate.

▸OutcomeL0073
Explain like I'm five
What
She labels this 'Outcome' next to the severity tiers but doesn't state what the outcome actually is.
▸AKIN criteriaL0074
Explain like I'm five
What
AKIN is the second grading system on this slide, alongside RIFLE, for the same kidney-injury severity.
Why
She names AKIN as a second system without stating why it exists alongside RIFLE or when to use one over the other.
Two staging systems for the same criteria

RIFLE and AKIN both grade AKI severity from the same two measurements — the rise in creatinine and the fall in urine output — but RIFLE keeps two tiers AKIN does not have.

RIFLE5 tiers: Risk, Injury, Failure, Loss, End-stage→sCreatinine + urine outputAKIN3 tiers: Stage 1, Stage 2, Stage 3→sCreatinine + urine output

AKIN stops at Stage 3; RIFLE continues to Loss and End-stage.

Explain like I'm five
What
RIFLE (Risk, Injury, Failure, Loss, End-stage) and AKIN (Stage 1, Stage 2, Stage 3) grade AKI from the same two measurements: serum creatinine and urine output.
Where
AKIN's table sits directly after RIFLE's, under the same 'Classification of kidney injury' heading, using the identical creatinine/urine-output layout.

Why this matters: A reported stage doesn't carry its system with it — Loss and End-stage have no AKIN number to map to, so a stage read off one system cannot be assumed to mean the same severity on the other.

▸sCreatinineL0075
Explain like I'm five
What
AKIN's first measurement, the same idea as RIFLE's: the rise in blood creatinine.
Why
She doesn't state why creatinine, rather than another marker, was chosen as one of the two measured criteria.
▸Urine output criteriaL0076
Explain like I'm five
What
AKIN's second measurement, the same idea as RIFLE's: how low urine output falls.
Why
She doesn't state why AKIN kept the same per-kg urine-output measure as RIFLE rather than defining a new one.
▸Stage 1: ↑ sCrea × 1.5 or ↑≥0.3 mg/dl in sCrea | < 0.5 ml/kg per h × 6 hL0077
Explain like I'm five
What
AKIN's mildest tier, Stage 1, is given as two criteria side by side: creatinine up 1.5-fold or risen by at least 0.3 mg/dl; urine output under 0.5 ml/kg/h.
Why
She doesn't state why AKIN adds the absolute 0.3 mg/dl option that RIFLE's matching Risk tier doesn't have.
When
The urine-output route requires that low output to hold for at least 6 hours, same as RIFLE's Risk tier.
▸Stage 2: ↑sCrea × 2 | < 0.5 ml/kg per h × 12 hL0078
Explain like I'm five
What
AKIN's middle tier, Stage 2, is given as two criteria side by side: creatinine up 2-fold; urine output under 0.5 ml/kg/h.
Why
As with RIFLE's matching tier, she doesn't state why the urine-output window doubles from Stage 1 to Stage 2.
When
The urine-output route requires that output to persist for at least 12 hours.
▸Stage 3: ↑sCrea × 3 or ↑≥0.5 mg/dl if baseline sCrea > 4.0 mg/dl | < 0.3 ml/kg per h × 24 h or anuria × 12 hL0079
Explain like I'm five
What
AKIN's most severe tier, Stage 3: creatinine up 3-fold, or a jump of at least 0.5 mg/dl once baseline already exceeds 4.0 mg/dl.
Why
As with RIFLE's Failure tier, she doesn't state why this smaller absolute rise counts once creatinine already exceeds 4.0 mg/dl.
When
By urine output: under 0.3 ml/kg/h for 24 hours, or complete anuria for as little as 12 hours — identical to RIFLE's Failure tier.
▸Patients who receive RRT are considered to have met stage 3 criteria, irrespective of the stage they are in at the time of RRT.exceptionL0080
Explain like I'm five
What
Anyone already on renal replacement therapy is automatically scored as AKIN Stage 3, regardless of their actual numbers.
Why
She states the rule but not why being on RRT is defined as meeting Stage 3.
ExceptionA patient already on RRT counts as AKIN Stage 3 by definition, regardless of the sCreatinine/urine-output criteria actually met.

KIDIGO Classification of AKI exception[L0082–L0082]

Exception · source errorHer KDIGO table gives Stage 1 and Stage 2 the same urine output, <0.5 mL/kg/h for 6-12 h, so the two stages cannot be separated on that criterion.
▸![figure](slide08.png)Slide 8figure_refL0082
Slide 8 — 'KIDIGO Classification of AKI' (her spelling), full staging tableSlide 8 — 'KIDIGO Classification of AKI' (her spelling), full staging table

Stage 1: SCr 1.5–1.9 times baseline OR ≥26.5 μmol/L (0.3 mg/dL) increase | Urine output &lt;0.5 mL/kg/h for 6–12 h. Stage 2: SCr 2–2.9 times baseline | Urine output &lt;0.5 mL/kg/h for 6–12 h. Stage 3: SCr 3 times baseline OR initiation of renal replacement therapy OR (in patients &lt;18 years) decrease in eGFR to &lt;35 mL/min per 1.73 m² | Urine output: anuria for ≥12 h.

The KDIGO table itself, in full — the numeric SCr multiples, the absolute μmol/L/mg/dL threshold, the paediatric eGFR clause, and the RRT-initiation clause for Stage 3 — none of which exist as text anywhere else in the deck. The only text row for this slide was the bare heading.

Outline shown 3 of 6[L0084–L0097]

▸• DefinitionnavL0084
▸• ClassificationnavL0085
▸• EpidemiologynavL0086
▸• Approaching AKI causes:navL0087
▸PrerenalnavL0088
▸Renal parenchymalnavL0089
▸Post renalnavL0090
▸• ManagementnavL0091
▸• OutcomenavL0092
▸• Other causes of AKInavL0093
▸RhabdomyolysisnavL0094
▸Contrast inducednavL0095
▸Acute tumour lysis syndromenavL0096
▸![figure](slide09.png)Slide 9figure_refL0097

Epidemiology[L0099–L0106]

▸• Using the KDIGO definition, 1 in 5 adults and 1 in 3 children worldwide experience AKI during a hospital episode of care.L0099
L0100
Explain like I'm five
What
Using the KDIGO definition, about 1 in 5 adults and 1 in 3 children develop AKI at some point during a hospital stay.
When
Any time over the course of an inpatient episode, not specifically on admission.
▸• Community-acquired AKI on admission to hospital affects approximately 5% in the UK (superimposed on CKD in half of these patients).L0101
L0102
L0103
Explain like I'm five
What
About 5% of UK hospital admissions already have AKI that started in the community before arrival; half of those already have CKD too.
Where
UK figures specifically, and community-acquired — before any hospital-acquired component.
▸• About 25% of patients with sepsis and 50% of patients with septic shock will have AKI.L0104
L0105
Explain like I'm five
What
AKI affects about 1 in 4 patients with sepsis, and about 1 in 2 patients with septic shock — two separate figures, not a rise from one into the other.
Same dimension, two severities compared

AKI incidence rises with how severe the infection is: sepsis versus septic shock, same measure.

sepsis25%septic shock50%
Explain like I'm five
What
About 25% of patients with sepsis, and 50% of patients with septic shock, will have AKI — the same outcome at two severities of infection.
Where
Both figures are stated in the same sentence on the Epidemiology slide, right after the UK admission-rate figure.

Why this matters: The two figures come from different populations in the same sentence — sepsis alone versus septic shock — so citing '25%' or '50%' without saying which group it describes over- or understates the other group's risk.

▸![figure](slide10.png)Slide 10figure_refL0106
Slide 10 — EpidemiologySlide 10 — Epidemiology

Three bullets matching the rows above verbatim. '1 in 5 adults and 1 in 3 children', '25% of patients with sepsis' and '50% of patients with septic shock' are highlighted yellow.

Highlighting picks out the four numbers she wants remembered from the three bullets; the 5% UK community-acquired figure is left unhighlighted.

Outline shown 4 of 6[L0108–L0121]

She says this again

This Outline slide repeats, word for word, the same bullet list already given at the row above.

Explain like I'm five
What
Repeats the same bullet list — Definition, Classification, Epidemiology, Approaching AKI causes, Management, Outcome, Other causes of AKI — word for word from the earlier Outline slide.
Where
Appears right after the Epidemiology section closes, marking a section break rather than new content.

Why this matters: Recognising the repeat as a section marker, not new content, stops the same bullet list from being read twice as if it were two different facts.

▸• DefinitionnavL0108
▸• ClassificationnavL0109
▸• EpidemiologynavL0110
▸• Approaching AKI causes:navL0111
▸PrerenalnavL0112
▸Renal parenchymalnavL0113
▸Post renalnavL0114
▸• ManagementnavL0115
▸• OutcomenavL0116
▸• Other causes of AKInavL0117
▸RhabdomyolysisnavL0118
▸Contrast inducednavL0119
▸Acute tumour lysis syndromenavL0120
▸![figure](slide11.png)Slide 11figure_refL0121

Approaching AKI[L0123–L0123]

Slide 12 — Approaching AKI, anatomical obstruction sitesSlide 12 — Approaching AKI, anatomical obstruction sites

Three red circles name the three categories on one urinary tract: A - Pre-Renal obstruction around the renal artery where it leaves the aorta; C - Intra-renal obstruction around the left kidney; B - Post Renal obstruction around the upper ureters. Small uncircled hatch-marks then repeat the letters at every level the type can occur - A on both renal arteries, C on both kidneys, B on both ureters and again at the prostate and urethra.

The picture puts all three categories on one drawing, so post-renal is visibly the only one with several possible levels - ureter, bladder outlet, prostate, urethra - while pre-renal and intra-renal each have one.

▸![figure](slide12.png)Slide 12figure_refL0123

Pre renal[L0125–L0137]

Slide 13Slide 13

Top node reads &darr;GFR — the falling arrow is the diagram's subject. One branch, 'Changes in the circulation', lists three drivers: hypovolaemia, hypotension without hypovolaemia, and low cardiac output. The other branch, 'Intra-renal causes (disturbed renal autoregulation)', names NSAIDs and ACE inhibitors.

The diagram's connecting arrows from GFR to each branch were not captured as text — the rows list the same content as separate lines with no arrow between them.

▸GFRL0125
Explain like I'm five
What
The thing at the centre of the diagram: pre-renal AKI is a fall in GFR, and the two boxes around it are the routes that cause that fall.
Where
Top of the pre-renal causes diagram, feeding from the 'changes in the circulation' and 'intra-renal causes' branches below it.
Two branches of pre-renal AKI, side by side

Both lower GFR. One is a whole-body circulation problem, the other is the kidney's own autoregulation being disturbed. The items inside each branch are alternatives, not a sequence.

changes in the circulationhypovolaemia of any cause; hypotension without hypovolaemia; low cardiac outputintra-renal, disturbed autoregulationNSAIDs; ACE inhibitors

Same effect, two different starting points.

Explain like I'm five
What
Pre-renal AKI splits into two branches: changes in the circulation (hypovolaemia, hypotension without hypovolaemia, low cardiac output) and disturbed renal autoregulation (intra-renal, NSAIDs, ACE inhibitors).
Why
Both branches lower GFR from different starting mechanisms — a whole-body circulation problem versus a kidney-level autoregulation disturbance — not one shared cause.

Why this matters: Both branches are grouped under one heading (pre-renal) and produce the same fall in GFR from different starting points — a whole-body circulation problem versus a drug disturbing the kidney's own autoregulation — so conflating them hides which mechanism is driving the injury.

▸Changes in the circulation:frameL0126
▸•hypovolaemia of any cause, including dehydration or haemorrhageL0127
L0128
Explain like I'm five
What
Hypovolaemia from any cause — she names dehydration and haemorrhage — is one of the three circulatory causes of pre-renal AKI listed here.
▸• hypotension without hypovolaemia, including cirrhosis or septic shockL0129
L0130
Explain like I'm five
What
Hypotension without hypovolaemia — cirrhosis or septic shock are her examples — is a second circulatory route: the driving pressure drops even though volume is normal.
▸• low cardiac output, including cardiac failure or cardiogenic shockL0131
L0132
Explain like I'm five
What
Low cardiac output, from heart failure or cardiogenic shock, is the third circulatory cause: the pump fails to deliver enough blood to the kidney.
▸Intra-renal causes: (disturbed renal autoregulation)L0133
L0134
L0135
Explain like I'm five
What
The second branch: intra-renal causes, meaning the kidney's own autoregulation of blood flow is disturbed rather than the whole-body circulation failing.
Where
Still classed under Pre-renal on this slide, even though the disturbance sits inside the kidney's own arterioles.
▸NSAIDs, ACE inhibitorsL0136
Explain like I'm five
What
NSAIDs and ACE inhibitors are her two named drug examples for the 'disturbed renal autoregulation' branch of pre-renal causes.
▸![figure](slide13.png)Slide 13figure_refL0137

Autoregulation[L0139–L0148]

Expands the autoregulation named two rows earlier

The Pre-renal slide names 'disturbed renal autoregulation' as an intra-renal cause; this slide gives the three substances that do the regulating.

Same mechanism, unpacked one slide later.

Explain like I'm five
What
Names the three substances that regulate the kidney's own blood flow: prostaglandins, nitric oxide, and angiotensin acting on the afferent and efferent arterioles.
Where
Given on the very next slide after 'disturbed renal autoregulation' is named as a pre-renal, intra-renal cause, unpacking that phrase.

Why this matters: Without this slide, 'disturbed renal autoregulation' on the earlier slide names a mechanism with no stated substances behind it.

Figure - autoregulation, four panelsFigure - autoregulation, four panels

A Normal labels the afferent arteriole, the efferent arteriole, the smooth muscle and the glomerulus, with a legend separating glomerular filtration from blood flow. B Stimulus: reduced renal perfusion &rarr; &darr;transglomerular pressure &rarr; &darr;GFR. C Response: intrarenal activation of the renin-angiotensin system &rarr; efferent arteriolar vasoconstriction &rarr; increases transglomerular pressure &rarr; restores GFR. A fourth panel draws Renin &rarr; A I &rarr; A II with the constriction marked on the efferent arteriole.

The picture carries the step the bullet list does not: the arteriole angiotensin constricts to rescue GFR is the efferent one. Squeezing the outflow raises pressure across the filter; squeezing the inflow would lower it.

▸• ProstaglandinsL0139
L0140
Explain like I'm five
What
Prostaglandins are one of three substances she lists as regulating the kidney's own blood flow.
▸• nitric oxideL0141
L0142
Explain like I'm five
What
Nitric oxide is the second of the three autoregulation mediators she names, alongside prostaglandins and angiotensin.
▸• angiotensin acting on afferent and efferent arteriolesL0143
L0144
L0145
L0146
L0147
Explain like I'm five
What
Angiotensin is the third mediator, and the only one she names as acting on both the afferent and the efferent arteriole.
Why
Constricting the outflow holds pressure up across the filter, which is how the kidney defends GFR when perfusion falls. She lists ACE inhibitors separately as an intra-renal cause of AKI.
How
Panel C of this slide names the arteriole that matters: renin-angiotensin activation constricts the efferent one, which raises transglomerular pressure and restores GFR.
▸![figure](slide14.png)Slide 14figure_refL0148

Is it prerenal or renal? shown 1 of 3[L0150–L0156]

▸In Prerenal :frameL0150
▸HistoryL0151
Explain like I'm five
What
History is named as one of the two tools for assessing suspected pre-renal AKI; she gives no detail on what to ask.
▸Clinical Examination:frameL0152
▸Assessment of volume status : signs of dehydration or hypovolemia (low BP, rapid pulse, sunken eyes, collapsed neck veins)L0153
L0154
L0155
Explain like I'm five
What
The physical signs of volume depletion she groups as one set: low blood pressure, a rapid pulse, sunken eyes, and collapsed neck veins.
Why
These are signs of hypovolaemia — the same circulatory cause of pre-renal AKI already named earlier on this slide.
▸![figure](slide15.png)Slide 15figure_refL0156

Is it prerenal or renal? shown 2 of 3[L0158–L0166]

▸Blood urea nitrogen : Creatinine ratioL0158
Explain like I'm five
What
The BUN-to-creatinine ratio — the value used next to judge pre-renal versus renal AKI.
▸>20:1 (BUN:C) or >40:1 (U:C) suggests pre-renal cause (less urea is being filteredL0159
L0160
L0161
Explain like I'm five
What
A BUN:creatinine ratio above 20:1, or a urea:creatinine ratio above 40:1, points to a pre-renal cause of AKI.
Why
In pre-renal AKI less urea is being filtered out, so it builds up in the blood faster than creatinine does.
What causes the BUN:creatinine ratio to rise in pre-renal AKI

The cutoff is not just an association — the lecture states the hormonal mechanism behind it.

Hypovolaemia is almost always associated with high…→>20:1 (BUN:C) or >40:1 (U:C) suggests pre-renal cause…

Explain like I'm five
What
That disproportionate rise is what produces the pre-renal cutoff: >20:1 (BUN:C) or >40:1 (U:C).
How
The chain runs hypovolaemia → high ADH → increased reabsorption of water and urea → disproportionate rise in the urea:creatinine ratio, exactly as her 'Explanation:' states it.

Why this matters: Knowing the ADH-driven mechanism, not just the cutoff number, is what lets the ratio be read as pre-renal evidence rather than an isolated lab value.

▸Explanation:frameL0162
▸Hypovolaemia is almost always associated with high levels of ADH causing increased reabsorption of water and urea and a disproportionate rise in the plasma urea: creatinine ratio.L0163
L0164
L0165
Explain like I'm five
What
Hypovolaemia raises ADH, and ADH increases reabsorption of both water and urea.
How
This pulls urea back up disproportionately more than creatinine, which is why the ratio rises in pre-renal AKI.
▸![figure](slide16.png)Slide 16figure_refL0166
Not in the markdown — read from the slideSlide 16Full text-slide screenshot, not a separate diagram: the same BUN:creatinine text already in the rows above. Her own emphasis: 20:1 and pre-renal are printed in red, along with the word Explanation:, while &gt;40:1 stays plain black — she marks the BUN:C ratio (20:1) as the one to remember, not the U:C ratio (40:1).

Is it prerenal or renal? shown 3 of 3[L0168–L0177]

▸XL0168
Explain like I'm five
What
She writes a lone 'X' on this slide; the lecture does not say what it marks.
▸FENa, calculated by measuring creatinine and sodium levels in the blood and urine simultaneously [(urinary sodium × serum creatinine)/(urinary creatinine × serum sodium)×100)L0169
L0170
L0171
L0172
L0173
L0174
L0175
L0176
Explain like I'm five
What
FENa is calculated from creatinine and sodium measured in blood and urine at the same time.
How
Formula given: (urinary sodium × serum creatinine) divided by (urinary creatinine × serum sodium), times 100.
Two tests for pre-renal versus renal AKI, and where each cutoff is stated

The lecture gives a diagnostic cutoff for the BUN:creatinine ratio in the text and gives the FENa cutoff on the slide 17 table rather than in the text rows.

in the textBUN:creatinine ratio — >20:1 (or urea:creatinine >40:1) suggests pre-renalon the slide 17 tableFENa — <1% pre-renal, >1% intrinsic; not given in the text rows
Explain like I'm five
What
Two tests distinguish pre-renal from renal AKI: the BUN:creatinine ratio (>20:1, or urea:creatinine >40:1) and FENa (<1% pre-renal, >1% intrinsic).
Where
The BUN:creatinine cutoff is stated in the text rows; the FENa cutoff appears only on the slide 17 table, not in the extracted text.

Why this matters: Both cutoffs are part of the lecture, but only one is in the extracted text rows — missing the slide table would wrongly read FENa as a formula with no stated threshold.

▸![figure](slide17.png)Slide 17figure_refL0177
Slide 17Slide 17

Table, 4 rows x 2 columns (Pre-renal | Intrinsic): Urine specific gravity — &gt;1.020 | &lt;1.010. Urine osmolality (mOsm/kg) — &gt;500 | &lt;350. Urine sodium (mmol/L) — &lt;10 | &gt;20. FeNa — &lt;1% | &gt;1%. A boxed note below repeats the FeNa formula text already in the rows.

The full pre-renal vs intrinsic lab cutoff table — specific gravity, osmolality, urine sodium and FeNa thresholds — none of which appear anywhere in the extracted text rows.

Management of prerenal AKI[L0179–L0187]

▸• Most cases of AKI have an element of hypovolaemia, so prompt fluid resuscitation is most often indicated.L0179
L0180
Explain like I'm five
What
Most AKI cases involve some degree of hypovolaemia.
Why
So prompt fluid resuscitation is the most commonly indicated treatment.
▸• When there is uncertainty as to the volume status of a patient, a fluid challenge of 250 mL crystalloid will often prove whether hypotension is fluid-responsive.L0181
L0182
L0183
Explain like I'm five
What
A 250 mL crystalloid fluid challenge is used to test whether low blood pressure is fluid-responsive.
When
Given when it is unclear whether the patient's volume status is the cause of hypotension.
▸• Crystalloids and particularly balanced solutions such as plasmalyte and Ringer’s lactate are the recommended resuscitative fluidL0184
L0185
L0186
Explain like I'm five
What
Crystalloids, especially balanced solutions such as plasmalyte and Ringer's lactate, are the recommended resuscitation fluids.
▸![figure](slide18.png)Slide 18figure_refL0187
Not in the markdown — read from the slideSlide 18A blue IV fluid-bag clipart icon beside the heading; no labels or values on it. Body text matches the fluid-resuscitation bullets already in the rows, highlighted in yellow. Her own emphasis: three phrases are highlighted in yellow on the slide - fluid resuscitation, fluid challenge of 250 mL crystalloid, and Crystalloids and particularly balanced solutions such as plasmalyte and Ringer’s lactate. The text conversion keeps the words and drops the emphasis.

Post-renal AKI[L0189–L0197]

▸• Causes:frameL0189
▸➢prostate disease in menL0190
Explain like I'm five
What
Prostate disease in men is one cause of post-renal AKI.
Where
In men, via obstruction of the outflow tract at the prostate.
▸➢bilateral ureteric obstruction (stones or tumours)L0191
Explain like I'm five
What
Bilateral obstruction of both ureters, from stones or tumours, is another cause of post-renal AKI.
Why one says "bilateral" and the other does not

AKI needs the whole outflow blocked. Count the tubes at each level.

below bladder1 urethra→one blockage is enough — prostate disease in menabove bladder2 ureters→both must be blocked — bilateral ureteric obstruction

Block one ureter and the other kidney carries on; below the bladder there is nothing to carry on with.

Explain like I'm five
What
Below the bladder there is one urethra, so one blockage (prostate disease) causes obstruction; above the bladder there are two ureters, so both must be blocked.
Where
Below the bladder (urethra) versus above the bladder (ureters) — the two anatomical levels named as post-renal AKI causes.

Why this matters: The word 'bilateral' only makes sense once the tube count at each level is counted — without it, the ureter case and the urethra case look like the same kind of blockage.

▸• History and Examination: e.g hesitancy frequency in Prostatic hypertrophyL0192
L0193
Explain like I'm five
What
Example: hesitancy and frequency on history point to prostatic hypertrophy in post-renal AKI.
▸Palpable bladder and suprapubic dullnessL0194
Explain like I'm five
What
Other examination findings suggesting obstruction: a palpable bladder and suprapubic dullness.
▸• Ultrasound must be done to exclude obstruction, as, once this is relieved (and if acute), renal function will return to baseline.L0195
L0196
Explain like I'm five
What
Ultrasound must be done to exclude obstruction as a cause of AKI.
Why
Because if obstruction is found and relieved in an acute case, kidney function returns to baseline.
▸![figure](slide19.png)Slide 19figure_refL0197
Slide 19Slide 19

Hydronephrosis diagram, Healthy Kidney vs Hydronephrosis side by side. Labels: Kidney, Ureter, Full bladder, Urethra. An arrow runs upward from the bladder toward the kidney, numbered: 1. The bladder is unable to empty; 2. The pressure is transmitted to the kidney; 3. There is a build-up of fluid in the kidney.

Her own emphasis: Ultrasound must be done is highlighted in yellow - the action she marks as non-optional on this slide.

Renal parenchymal AKI shown 1 of 2[L0199–L0205]

▸80-90 % Acute tubular necrosisL0199
Explain like I'm five
What
Acute tubular necrosis (ATN) accounts for 80-90% of renal parenchymal (intrinsic) AKI - the dominant cause by far.
Where
The tubules, not the glomerulus or the vessels - that's what 'tubular' names in the term itself.
Two named routes into ATN

Acute tubular necrosis, 80-90% of renal parenchymal AKI, arises from either of two named causes.

prolonged prerenala low-flow state that persists - no mechanism to ATN statednephrotoxins, e.g. aminoglycosidescauses direct injury and cell death in the renal tubules

One route has a stated mechanism; the other doesn't.

Explain like I'm five
What
ATN is 80-90% of renal parenchymal AKI, arising from either prolonged prerenal AKI (a persisting low-flow state) or nephrotoxins such as aminoglycosides.
How
Both routes have a stated mechanism: nephrotoxins cause direct tubular injury and cell death; the prerenal route runs through the vasoconstriction-hypoxia-tubular injury chain given under 'Pathogenesis of ATN' (the rows below).

Why this matters: Same endpoint (ATN), different action: prolonged prerenal AKI is addressed by restoring perfusion (fluid resuscitation, the rows above); the nephrotoxin route is addressed by withholding/avoiding the drug (the rows below) or, if it caused the AKI, RRT to remove it (the row below).

▸Prolonged prerenalL0200
Explain like I'm five
What
One of two named routes into ATN: a prerenal (low renal blood flow) problem that persists instead of resolving quickly.
How
'Pathogenesis of ATN' gives it: intrarenal vasoconstriction cuts O2, causing tubular hypoxia and endothelial/tubular cell damage (the rows below), and tubular cells' high metabolic rate makes them most vulnerable to that ischaemia (the rows below).
▸nephrotoxins causing direct injury and cell death in renal tubules( Drugs, e.g. aminoglycosides)L0201
L0202
L0203
L0204
Explain like I'm five
What
The second named route into ATN: nephrotoxins - drugs such as aminoglycosides - causing direct injury and cell death in the renal tubules.
How
Direct injury and cell death: she states the toxin acts straight on the tubule cells, with no intermediate step named.
▸![figure](slide20.png)Slide 20figure_refL0205
Renal parenchymal AKI - ATN causes (slide 20)Renal parenchymal AKI - ATN causes (slide 20)

Two curved arrows drop from the '80-90% Acute tubular necrosis' header at top-centre: one down-left, arrowhead into 'nephrotoxins causing direct injury and cell death in renal tubules (Drugs, e.g. aminoglycosides)'; one down-right, arrowhead into 'Prolonged prerenal'.

Confirms these are two parallel, independent routes into ATN - both arrows originate from the same ATN header and neither points to the other - the same two causes already listed in the text, drawn as a branching diagram rather than stated as new.

Renal parenchymal AKI shown 2 of 2[L0207–L0216]

▸Renal ParenchymalframeL0207
Renal parenchymal AKI, split by site

Renal parenchymal (intrinsic) AKI is split into three categories by which kidney structure is damaged.

Glomerularacute rapidly progressive GNAcute Tubulointerstitialno example givenVascularvasculitis, accelerated hypertension, cholesterol embolism, HUS

Three sites named; only two given worked examples.

Explain like I'm five
What
Three categories by damaged structure: Glomerular (acute rapidly progressive GN), Acute Tubulointerstitial (no example given), and Vascular (vasculitis, accelerated hypertension, cholesterol embolism, HUS).
Where
Named on the second 'Renal parenchymal AKI' slide, directly after ATN's two routes on the first.

Why this matters: Which structure is damaged sets the workup for at least one branch — glomerular disease points to the immune profile ordered when GN is suspected — but the deck names no corresponding test for the vascular or tubulointerstitial categories, so treating 'renal parenchymal AKI' as one bucket loses that distinction.

▸GlomerularL0208
Explain like I'm five
What
One of three site-based categories of renal parenchymal AKI: damage at the glomerulus, with acute rapidly progressive GN given as the example.
Where
The glomerulus - the kidney's filtering unit.
▸Acute rapidly progressive GNL0209
L0210
Explain like I'm five
What
The example given for glomerular-type renal parenchymal AKI: acute rapidly progressive glomerulonephritis (GN).
▸Acute TubulointerstitialL0211
Explain like I'm five
What
A second category of renal parenchymal AKI, alongside Glomerular and Vascular: damage sited in the tubules and interstitium. Unlike the other two, no example diagnosis is given for it here.
Where
The tubules and the interstitial tissue surrounding them.
▸VascularL0212
Explain like I'm five
What
The third site-based category of renal parenchymal AKI: damage to the kidney's own blood vessels, with four named examples below it.
Where
The renal vasculature, as distinct from the glomerulus or the tubules.
▸vasculitis accelerated hypertension, cholesterol embolism, HUSL0213
L0214
L0215
Explain like I'm five
What
Four named examples of vascular-type renal parenchymal AKI: vasculitis, accelerated hypertension, cholesterol embolism, and HUS.
▸![figure](slide21.png)Slide 21figure_refL0216

Pathogenesis of ATN[L0218–L0223]

▸• Intrarenal microvascular vasoconstriction O 2 tubular hypoxiaL0218
L0219
Explain like I'm five
What
The sequence given for ATN's pathogenesis: constriction of the kidney's small vessels, a drop in oxygen, then tubular hypoxia.
How
The slide draws it as one chain: intrarenal microvascular vasoconstriction cuts oxygen delivery, and the tubule is left hypoxic. The text conversion dropped those arrows; the figure on this slide restores them.
Vasoconstriction to hypoxia, arrows lost in conversion

The bullet lists vasoconstriction, a drop in oxygen, then tubular hypoxia in sequence; the arrows that joined them were dropped when the slide converted to text.

The sequence survives; the connecting symbols do not.

Explain like I'm five
What
Lists, in order: intrarenal microvascular vasoconstriction, a drop in oxygen, then tubular hypoxia.
Where
First bullet under 'Pathogenesis of ATN', before endothelial/vascular damage and tubular cell injury.

Why this matters: The slide draws vasoconstriction, falling oxygen and tubular hypoxia as one causal chain with arrows; naming the lost arrows keeps the three terms from being read as an unordered list.

▸• Increased endothelial and vascular smooth muscle cell structural damageL0220
L0221
Explain like I'm five
What
A separate bullet under Pathogenesis of ATN: structural damage to the endothelial and vascular smooth muscle cells. The slide draws no arrow tying it to the bullet above.
▸• Tubular cell injuryL0222
Explain like I'm five
What
The third bullet under Pathogenesis of ATN: injury to the tubular cells themselves. Listed alongside the others, not drawn as following them.
▸![figure](slide22.png)Slide 22figure_refL0223
Pathogenesis of ATN (slide 22)Pathogenesis of ATN (slide 22)

Only the first bullet carries arrows: 'Intrarenal microvascular vasoconstriction' [arrow] a downward arrow before 'O2' [arrow] 'tubular hypoxia' - one straight left-to-right chain of three terms. The second bullet ('Increased endothelial and vascular smooth muscle cell structural damage') and third bullet ('Tubular cell injury') sit below as separate, unconnected bullet points - no arrows link them to the first bullet or to each other.

Restores the exact arrows the text conversion lost: vasoconstriction causes decreased O2, which causes tubular hypoxia - one causal chain, not three independent labels. The other two bullets are NOT drawn as later steps in that chain; they stand alone with no arrow, so the diagram does not support reading this as a four-step ordered pathogenesis.

Acute Tubular Necrosis[L0225–L0234]

▸![figure](slide23.png)Slide 23figure_refL0225
Acute Tubular Necrosis - nephron diagram (slide 23)Acute Tubular Necrosis - nephron diagram (slide 23)

A single nephron drawn top to bottom. An afferent arteriole enters a glomerular loop labelled 'Decreased glomerular filtration rate', with 'Afferent arteriolar constriction' at the entering vessel. The tube runs down into a tubule labelled 'Ischemic/toxic insult', where two arrows point to 'Back-leak' and 'Tubular injury'. The tubule lumen at the bottom is filled with debris labelled 'Obstruction'.

The image sites each of the six terms at a specific point on one nephron and its arrows show flow/leak direction, not one term causing another - the flat text list gives no such order or link between them.

▸Afferent arteriolar constrictionfigure_refL0226
▸Decreased glomerular filtration ratefigure_refL0227
▸Ischemic/toxic insultfigure_refL0228
▸Back-leakfigure_refL0229
▸Tubular injuryfigure_refL0230
▸Obstructionfigure_refL0231
▸• Tubular epithelial cells have a high metabolic rateL0232
Explain like I'm five
What
Tubular epithelial cells run a high metabolic rate compared with other renal cells.
Where
In the lining of the renal tubule.
▸• Most vulnerable to ischemic injuryL0233
Explain like I'm five
What
Of all renal cell types, tubular epithelial cells are the most vulnerable to ischemic injury.
Why
She states they are most vulnerable to ischemic injury but does not connect this to the high metabolic rate stated on the line above - no 'because' is given.
▸Copyright © 2015 Wolters Kluwer • All Rights ReservedmetaL0234

Clinical picture[L0236–L0242]

▸• Oliguria is common in the early stages; non-oliguric AKI is usually the result of a less severe renal insult.L0236
L0237
Explain like I'm five
What
Oliguria (reduced urine output) is the typical early pattern in AKI. When output is preserved instead — non-oliguric AKI — that itself points to a milder renal insult.
Why
She links insult severity to urine output (milder insult → non-oliguric) but does not explain why severity determines whether output is preserved.
When
Oliguria is described as an early-stage finding specifically.
▸• ATN classically passes into 4 phases : onset, oliguric, diuretic and recoveryL0238
L0239
Explain like I'm five
What
ATN classically runs a fixed four-phase course, in order: onset, oliguric, diuretic, then recovery.
Why
She states ATN passes through these four phases but does not explain why the injury follows this particular sequence.
How
She names the four phases but does not state what drives the transition from one phase to the next.
▸• Recovery of renal function typically occurs after 7–21days, although recovery is delayed by continuing sepsis.exceptionL0240
L0241
Explain like I'm five
What
Kidney function typically recovers within 7 to 21 days of the injury.
Why
She states that continuing sepsis delays recovery. She does not state why.
When
The 7–21 day estimate holds when sepsis has resolved; it does not apply to that timeframe once sepsis is ongoing, per the stated exception.
ExceptionRecovery from AKI typically takes 7–21 days — except when sepsis continues, which delays it.
▸![figure](slide24.png)Slide 24figure_refL0242

Emergency investigation of AKI[L0244–L0254]

▸• Pre-renal, renal or post-renal AKI?frameL0244
▸Pre-renal AKI is diagnosed largely on clinical examination, and assessing the volume status is vital; it can be difficult to distinguish pre-renal and renal AKI (particularly since prolonged renal hypoperfusion will lead to ATN).exceptionL0245
L0246
L0247
L0248
Explain like I'm five
What
Pre-renal AKI is diagnosed mainly by clinical examination, with assessing volume status as the key step.
Why
Pre-renal and renal AKI can be hard to tell apart because prolonged reduced kidney blood flow (pre-renal) can itself turn into ATN (renal).
How
'Pathogenesis of ATN' names the steps: intrarenal vasoconstriction cuts oxygen delivery, causing tubular hypoxia and cell injury — tubular cells' high metabolic rate leaves them most vulnerable (the rows above).
ExceptionRule: AKI sorts into pre-renal, renal, post-renal. Exception: prolonged renal hypoperfusion becomes ATN, so pre-renal and renal can be difficult to distinguish.
▸Bladder outflow obstruction is ruled out byframeL0249
▸➢clinical examination (a large palpable bladder suggests longstanding outflow obstruction), after inserting a urethral catheter (or flushing of an existing catheter) and draining large urine volumesL0250
L0251
L0252
Explain like I'm five
What
A large, palpable bladder on exam suggests longstanding outflow obstruction; this is checked after passing (or flushing) a urethral catheter and seeing whether a large volume of urine drains.
Where
A bedside finding at the bladder itself, confirmed via catheter drainage.
When
The palpable-bladder finding specifically points to obstruction that has been present for some time, not an acute block.
▸➢ultrasound of the kidneys and bladderL0253
Explain like I'm five
What
Ultrasound of the kidneys and bladder is the second check used, alongside exam and catheterisation, to rule out outflow obstruction.
Why
She names ultrasound as the test used but does not state what finding on it would confirm obstruction.
▸![figure](slide25.png)Slide 25figure_refL0254
Not in the markdown — read from the slideslide25.png (end of Emergency investigation of AKI)A red 'EMERGENCY' alarm-bell clipart icon top-right; body text matches the rows already transcribed (pre/renal/post-renal question, bladder-outflow-obstruction bullets), with 'assessing the volume status is vital' highlighted yellow. Her own emphasis: assessing the volume status is vital is highlighted in yellow on the slide. The words survive the conversion; the emphasis does not.

Investigations shown 1 of 2[L0256–L0265]

▸Urinalysis, urine microscopy:frameL0256
▸• RBCs and red-cell casts (indicative of glomerulonephritis)L0257
Explain like I'm five
What
Red blood cells and red-cell casts in the urine point toward glomerulonephritis as the cause.
Why
She labels this finding indicative of glomerulonephritis and does not explain further.
▸• urine culture.L0258
Explain like I'm five
What
Urine sent for culture — the one test in this list that looks for an organism rather than a chemistry.
Why
She lists it among the urine tests without saying what a positive culture would change in the management of the AKI.
▸• Urine should be tested for free haemoglobin and myoglobin, where appropriate.L0259
L0260
Explain like I'm five
What
Urine is checked for free haemoglobin and myoglobin.
Why
She does not state why urine is tested for these two substances specifically.
When
She says this applies 'where appropriate' but does not state which clinical situations that covers.
▸• uPCR is helpful if parenchymal disease is possibleL0261
Explain like I'm five
What
Urine protein:creatinine ratio (uPCR) is a urine test used in the AKI work-up.
Why
She states only that uPCR is helpful when parenchymal disease is possible, and does not go further.
When
Used specifically when parenchymal (intrinsic renal) disease is a possible cause, not for pre- or post-renal causes.
▸• Urinary and plasma biomarkers (e.g. kidney injury molecule 1, NGAL rise within a few hours of AKI and may allow earlier treatment.L0262
L0263
L0264
Explain like I'm five
What
Newer urinary and plasma biomarkers — kidney injury molecule-1 and NGAL — are used to help detect AKI.
Why
She states this matters because these biomarkers may allow earlier treatment.
When
They rise within a few hours of the kidney injury.
▸![figure](slide26.png)Slide 26figure_refL0265

Investigations shown 2 of 2[L0267–L0274]

▸• serum urea, electrolytes, creatinine, calcium, phosphate, albumin, alkaline phosphatase and urate concentrationsL0267
L0268
Explain like I'm five
What
A panel of eight blood tests: urea, electrolytes, creatinine, calcium, phosphate, albumin, alkaline phosphatase and urate.
Why
She lists these eight markers as part of the AKI panel but does not state what each detects or why it is included.
▸• CBCL0269
Explain like I'm five
What
Complete blood count — the abbreviation she uses for the routine haematology panel.
Why
Listed without a stated purpose: she does not say which AKI cause a blood count is meant to point at.
▸• Coagulation studiesL0270
Explain like I'm five
What
A clotting screen, sent alongside the routine bloods.
Why
She names it but not what it rules in or out; the only bleeding-related risk she states is with anticoagulants, under management.
▸• blood culturesL0271
Explain like I'm five
What
Blood cultures are sent, alongside the routine bloods.
Why
Not linked here to a cause, though she states separately that about 25% of sepsis and 50% of septic shock patients have AKI.
▸• nephrotoxic drug blood levelsL0272
Explain like I'm five
What
Blood levels of nephrotoxic drugs are checked where relevant.
▸• Immune profile in suspected GNL0273
Explain like I'm five
What
An immune profile is sent as part of the AKI investigations.
When
Specifically when glomerulonephritis (GN) is suspected as the underlying cause.
▸![figure](slide27.png)Slide 27figure_refL0274

Abdominal and pelvic Ultrasound[L0276–L0283]

▸Indications of Renal Biopsy in AKI:frameL0276
▸o Significant unexplained urine abnormalities; proteinuria, and / or hematuriaL0277
L0278
Explain like I'm five
What
One trigger for biopsy: urine protein or blood present without a clear explanation.
Why
She lists this as a trigger but does not say why unexplained proteinuria or haematuria specifically points to a diagnosis biopsy could reveal.
▸o Persistent ATN more than 4 weeksL0279
Explain like I'm five
What
A trigger for biopsy: acute tubular necrosis that has not resolved on its own.
Why
She sets 4 weeks as the cutoff but does not explain why that duration, rather than another, is the trigger point.
When
Once persistent ATN has lasted longer than 4 weeks.
▸o Unclear EtiologyL0280
Explain like I'm five
What
A trigger for biopsy: the cause of the AKI remains unclear after the rest of the workup.
▸o Suspicion of a systemic diseaseL0281
Explain like I'm five
What
A trigger for biopsy: a systemic (body-wide) disease is suspected as the cause.
Why
She flags systemic disease as a trigger without naming which diseases, or why biopsy would help identify them.
▸Investigationsfigure_refL0282
▸![figure](slide28.png)Slide 28figure_refL0283

Outline shown 5 of 6[L0285–L0298]

▸• DefinitionnavL0285
▸• ClassificationnavL0286
▸• EpidemiologynavL0287
▸• Approaching AKI causes:navL0288
▸PrerenalnavL0289
▸Renal parenchymalnavL0290
▸Post renalnavL0291
▸• ManagementnavL0292
▸• OutcomenavL0293
▸• Other causes of AKInavL0294
▸RhabdomyolysisnavL0295
▸Contrast inducednavL0296
▸Acute tumour lysis syndromenavL0297
▸![figure](slide29.png)Slide 29figure_refL0298

Acute or chronic uremia?[L0300–L0335]

AKI vs CKD: lab and imaging clues

A prior creatinine reading, certain chronic biochemical changes, and kidney size on ultrasound each help tell a new kidney injury from long-standing kidney disease.

Point of comparison — Acute Kidney Injury (AKI) vs Chronic Kidney Disease (CKD) — dotted cells are her words from the rows below; solid ones are those rows condensed
Point of comparisonAcute Kidney Injury (AKI)Chronic Kidney Disease (CKD)
Previous serum creatininePrevious recent normal serum creatininePrevious abnormal high serum creatinine
Anemia, high PTH hyperphosphatemia, hypocalcaemia,Less commonMore common
Kidney size on ultrasound abdomenKidney is normal in sizeKidney is small except in patients with diabetes who have normal or large sized kidneys
Chronicity of symptomsAcute illness with acute/sudden onset of symptoms e.g. dyspnea, nausea, vomiting, diarrheaLong previous history of symptoms e.g. fatigue, nausea, nocturia, itching
Oliguria (anuria)CommonCommon
Explain like I'm five
What
Four of the five rows are one axis restated four ways: new versus old. A previous normal creatinine, sudden symptoms, and a normal-sized kidney all say 'new'; their opposites say 'old'.
Why
Oliguria breaks that pattern: the source marks it 'Common' in both columns, so it is the one criterion on this table that cannot separate AKI from CKD.

Why this matters: This table is how AKI is told from CKD before treatment: the deck's recovery statements (ATN recovering in 7–21 days, post-renal AKI returning to baseline) are made only about AKI, never about CKD.

▸Point of comparisonL0300
Explain like I'm five
What
Labels the left-hand column, naming the criterion each row below compares.
Where
Heading of the table's first column, above every AKI/CKD comparison that follows.
▸Acute Kidney Injury (AKI)L0301
Explain like I'm five
What
Names the middle column — the AKI value for every comparison below.
Where
Sits directly across from the CKD heading.
▸Chronic Kidney Disease (CKD)L0302
L0303
Explain like I'm five
What
Names the right-hand column — the CKD value for every comparison below.
Where
Paired opposite the AKI heading.
▸Laboratory InvestigationsframeL0304
▸Previous serum creatinineL0305
Explain like I'm five
What
The first lab criterion: what the patient's creatinine was reading before this illness.
Where
Listed above the anaemia/PTH/phosphate/calcium pattern, the other lab criterion in this group.
▸Previous recent normal serum creatinineL0306
L0307
Explain like I'm five
What
In AKI, the creatinine recorded before this episode was recently normal.
Where
The AKI-column value for the previous-creatinine criterion, opposite the CKD value in the row below.
▸Previous abnormal high serum creatinineL0308
L0309
Explain like I'm five
What
In CKD, the creatinine recorded before this episode was already abnormally high.
Where
The CKD-column value for the same previous-creatinine criterion, opposite the AKI value in the row above.
▸Anemia, high PTH hyperphosphatemia, hypocalcaemia,L0310
L0311
L0312
Explain like I'm five
What
A set of four biochemical changes: anaemia, raised PTH, high phosphate, low calcium.
Where
The second lab criterion, listed below previous creatinine in this group.
Why
She marks this pattern less common in AKI and more common in CKD, and does not go further.
▸Less commonL0313
Explain like I'm five
What
This biochemical pattern is less common in AKI.
Where
The AKI-column value for the anaemia/PTH/phosphate/calcium criterion, opposite the CKD value below.
▸More commonL0314
Explain like I'm five
What
The same biochemical pattern is more common in CKD.
Where
The CKD-column value for the same criterion, opposite the AKI value above.
▸RadiologyframeL0315
▸Kidney size on ultrasound abdomenL0316
L0317
Explain like I'm five
What
The imaging criterion: what the kidneys look like in size on abdominal ultrasound.
Where
The only criterion listed under Radiology.
▸Kidney is normal in sizeL0318
Explain like I'm five
What
In AKI, the kidney appears normal in size on ultrasound.
Where
The AKI-column value for the kidney-size criterion, opposite the CKD value below.
▸Kidney is small except in patients with diabetes who have normal or large sized kidneysexceptionL0319
L0320
L0321
L0322
Explain like I'm five
What
In CKD, the kidney is usually small on ultrasound.
Where
The CKD-column value for the kidney-size criterion, opposite the AKI value above.
Why
She states the diabetic exception without explaining why diabetic kidneys stay normal or large instead of shrinking.
ExceptionCKD usually gives small kidneys on ultrasound, except in diabetic patients, whose kidneys stay normal or large.
▸SymptomsframeL0323
▸Chronicity of symptomsL0324
Explain like I'm five
What
The criterion: how long the symptoms have been present.
Where
The only criterion listed under Symptoms here; its AKI/CKD values (sudden onset vs. long history) appear past this slice.
▸Acute illness with acute/sudden onset of symptoms e.g. dyspnea, nausea, vomiting, diarrheaL0325
L0326
L0327
L0328
Explain like I'm five
What
For AKI, symptoms are sudden — breathlessness, nausea, vomiting and diarrhoea all start acutely.
Why
This is the AKI side of the table's chronicity-of-symptoms row: abrupt onset is what marks a case acute rather than chronic.
Same dimension, opposite timing

Chronicity of symptoms splits the two conditions: AKI's symptoms start suddenly, CKD's have built up over a long history.

AKIsudden onset→dyspnea, nausea, vomiting, diarrheaCKDlong-standing history→fatigue, nausea, nocturia, itching
Explain like I'm five
What
AKI presents as acute illness with sudden-onset symptoms (dyspnea, nausea, vomiting, diarrhea); CKD presents with a long previous history of symptoms (fatigue, nausea, nocturia, itching).
Where
The 'Chronicity of symptoms' row of the AKI-versus-CKD comparison table.

Why this matters: Symptom timing is one of the ways this lecture tells acute injury apart from chronic disease.

▸Long previous history of symptoms e.g. fatigue, nausea, nocturia, itchingL0329
L0330
L0331
Explain like I'm five
What
For CKD, the same kind of symptoms — fatigue, nausea, nocturia, itching — have built up over a long time rather than starting suddenly.
Why
This is the CKD side of the same row: a long symptom history, the opposite of AKI's sudden onset, is what separates chronic from acute here.
▸Oliguria (anuria)L0332
Explain like I'm five
What
Introduces the table's second symptom-based comparison point between AKI and CKD: whether urine output falls (oliguria) or stops (anuria).
Where
Sits under the Symptoms category, alongside chronicity of symptoms, as one of two symptom-based rows in this comparison table.
Why
She doesn't say why oliguria/anuria was chosen as a comparison point, unlike chronicity of symptoms above.
Same value both conditions

Oliguria/anuria is marked common for both AKI and CKD — the one row in this comparison where the two conditions don't separate.

Explain like I'm five
What
Oliguria (anuria) is marked 'Common' under both the AKI column and the CKD column of this comparison table.
Why
This is the one row where the two conditions share the same value, unlike the other rows that split old versus new.

Why this matters: Shows this finding does not help distinguish acute from chronic kidney disease.

▸CommonL0333
Explain like I'm five
What
Oliguria or anuria is marked common in AKI on this comparison table.
Why
She marks it common in AKI without explaining why reduced urine output occurs in acute injury.
▸CommonL0334
Explain like I'm five
What
Oliguria or anuria is also marked common in CKD — the same value as the AKI column.
Why
Both columns read 'Common', making this the one row in the slice where the table does not separate the two conditions.
▸![figure](slide30.png)Slide 30figure_refL0335
slide30.png (Acute or chronic uremia? comparison table, end of slide)slide30.png (Acute or chronic uremia? comparison table, end of slide)

Closes the acute-vs-chronic comparison slide; its rows in this slice — chronicity of symptoms and oliguria/anuria — are already extracted as separate table_row lines above this marker.

Her own emphasis: every discriminating phrase in the table is underlined on the slide - the previous-creatinine pair, the kidney-size pair, and the oliguria pair that reads Common on both sides.

Management shown 1 of 2[L0337–L0345]

▸General measuresframeL0337
▸• Fluid balance, as intake and output (particularly urine output), will be key to recovery.L0338
L0339
Explain like I'm five
What
Tracking fluid intake and output, particularly urine output, is described as key to recovering from AKI.
When
She says fluid balance is key to recovery without stating how often it should be checked.
▸• Daily measurements of weight and lying and standing blood pressureL0340
L0341
Explain like I'm five
What
Weight and blood pressure, taken both lying and standing, are measured daily as part of general AKI management.
Why
She lists lying-and-standing blood pressure as a daily measurement without stating why the two positions are compared.
When
Done daily throughout management, not just once at initial assessment.
▸• medication review to withhold nephrotoxinsL0342
Explain like I'm five
What
Medications are reviewed specifically to identify and withhold nephrotoxic (kidney-damaging) drugs.
Why
She doesn't restate here why nephrotoxic drugs are withheld — only that the review happens.
▸• collateral history and past results will all form part of the management plan.L0343
L0344
Explain like I'm five
What
Collateral history and the patient's past results are both folded into the AKI management plan.
▸![figure](slide31.png)Slide 31figure_refL0345
slide31.png (general measures Management slide, end of slide)slide31.png (general measures Management slide, end of slide)

Closes the general-measures Management slide; its four bullets (fluid balance, daily weight/BP, medication review, collateral history) are already extracted as list items above this marker.

Her own emphasis: withhold nephrotoxins is highlighted in yellow among the general measures.

Management shown 2 of 2[L0347–L0356]

▸• Hyperkalaemia (refer to lecture of electrolyte imbalance)L0347
Explain like I'm five
What
Hyperkalaemia is listed as a complication to manage in AKI, but referred out to a separate electrolyte-imbalance lecture rather than explained here.
Where
First of six complication-specific items on this second Management slide, ahead of acid-base balance and the rest.
▸• Acid base balance (management of acidosis)L0348
Explain like I'm five
What
Acid-base balance — specifically managing acidosis — is the second complication listed for AKI management.
▸• Pulmonary edemaL0349
Explain like I'm five
What
Pulmonary oedema (fluid in the lungs) is listed as a complication to manage in AKI.
▸• SepsisL0350
Explain like I'm five
What
Sepsis is listed among the complications managed in AKI, with no detail given here.
▸• Use of drugsframeL0351
She says this again

Avoiding nephrotoxic drugs is stated twice: first as a general measure (medication review to withhold nephrotoxins), then again here with day-by-day dose adjustment and anticoagulants named as a particular risk.

Explain like I'm five
What
First stated as 'medication review to withhold nephrotoxins'; restated here as nephrotoxins must be avoided, with day-by-day dose adjustment and a named risk with anticoagulants.
Where
First Management slide (general measures) and this second Management slide, under 'Use of drugs'.

Why this matters: Repetition across both Management slides marks nephrotoxin avoidance as a recurring priority, not a one-off point.

▸Nephrotoxins must be avoided and all drug dosing adjustment on a day-by-day basis . There is a particular risk with anticoagulantsL0352
L0353
Explain like I'm five
What
Nephrotoxic drugs must be avoided, and every drug's dose re-adjusted, in AKI.
Why
She flags anticoagulants as a particular risk without explaining why they specifically carry more danger than other drug classes.
When
Dosing is adjusted continuously, day by day, rather than set once.
▸• NutritionframeL0354
▸Salt and potassium should be restricted.L0355
Explain like I'm five
What
Salt and potassium intake should be restricted as the nutritional measure in AKI.
Why
She doesn't say why salt and potassium specifically are restricted, rather than other nutrients.
▸![figure](slide32.png)Slide 32figure_refL0356
slide32.png (complication-specific Management slide, end of slide)slide32.png (complication-specific Management slide, end of slide)

Closes the second Management slide; its six bullets (hyperkalaemia, acid-base balance, pulmonary oedema, sepsis, drug use, nutrition) are already extracted above this marker.

Her own emphasis: Nephrotoxins must be avoided is highlighted in yellow - the same instruction she highlighted on the previous slide, marked twice.

Renal replacement Therapy[L0358–L0366]

▸Indications :frameL0358
▸• symptomatic uraemia (including encephalopathy, pericarditis or tamponade)L0359
L0360
Explain like I'm five
What
Symptomatic uraemia is an RRT indication, specifically when it causes encephalopathy, pericarditis, or cardiac tamponade.
Why
She doesn't explain why these three complications specifically mark uraemia as dangerous enough to need dialysis.
▸• hyperkalaemia not controlled by conservative measuresL0361
Explain like I'm five
What
RRT is indicated when hyperkalaemia can't be brought down with conservative (non-dialysis) measures.
When
Applies only once conservative measures have already been tried and failed, not as a first step.
▸• pulmonary oedema unresponsive to diuresisL0362
Explain like I'm five
What
RRT is indicated when pulmonary oedema fails to respond to diuretic treatment.
When
Applies only after diuresis has already been tried without success.
▸• severe acidosisL0363
Explain like I'm five
What
Severe acidosis alone is listed as an indication for RRT.
Why
She says 'severe' without stating where the threshold sits that counts as severe enough for RRT.
▸• for removal of drugs causing the AKI, e.g. gentamicin, lithium, severe aspirin overdose.L0364
L0365
Explain like I'm five
What
RRT is also used to remove drugs that caused the AKI itself — gentamicin, lithium, and severe aspirin overdose are named examples.
Why
She doesn't explain why dialysis can clear these particular drugs from the body.
▸![figure](slide33.png)Slide 33figure_refL0366

Renal replacement[L0368–L0374]

▸RRT options includeframeL0368
▸• intermittent haemodialysisL0369
Explain like I'm five
What
One RRT option: haemodialysis given in scheduled sessions rather than continuously.
▸• CRRTL0370
Explain like I'm five
What
CRRT: continuous renal replacement therapy, an option that runs continuously rather than in sessions. The next two lines name its two forms.
Where
Sits as the umbrella label directly above its two named forms, haemodiafiltration and CVVHF, which specify what CRRT means in practice.
Why
She does not state why a patient would receive continuous CRRT rather than intermittent haemodialysis.
Names its own subtypes

CRRT is not one technique but an umbrella term; the next two lines name its two specific forms.

Explain like I'm five
What
CRRT is followed immediately by two named forms: haemodiafiltration (HDF) and continuous venovenous haemofiltration (CVVHF).
Where
Listed under 'Renal replacement Therapy' options, alongside intermittent haemodialysis and peritoneal dialysis.

Why this matters: Reading 'CRRT' as one specific technique rather than an umbrella would blur it with the two named forms underneath it (HDF, CVVHF), which are what actually gets ordered and run.

▸haemodiafiltration (HDF)L0371
Explain like I'm five
What
One named form of CRRT: haemodiafiltration, abbreviated HDF.
▸continuous venovenous haemofiltration (CVVHF)L0372
Explain like I'm five
What
The other named form of CRRT listed here: continuous venovenous haemofiltration, abbreviated CVVHF.
▸• peritoneal dialysisL0373
Explain like I'm five
What
The third RRT option listed: peritoneal dialysis.
▸![figure](slide34.png)Slide 34figure_refL0374

Outline shown 6 of 6[L0376–L0397]

She says this again, with one line added

This Outline slide repeats the same bullet list shown on the lecture's earlier Outline slides, adding one line the earlier copies do not have: Acute Hyperuricemic nephropathy.

Explain like I'm five
What
Repeats the same Outline bullet list — Definition through Other causes of AKI (Rhabdomyolysis, Contrast induced, Acute tumour lysis syndrome) — and adds one new line: Acute Hyperuricemic nephropathy.
Where
Sixth and final appearance of this Outline slide (shown 6 of 6), just before the causes-of-AKI section resumes.

Why this matters: Spotting the repeat and its one addition marks Acute Hyperuricemic nephropathy as the new topic about to be covered, rather than reading the whole list as freshly introduced content.

▸• DefinitionnavL0376
L0377
▸• ClassificationnavL0378
L0379
▸• EpidemiologynavL0380
L0381
▸• Approaching AKI causes:navL0382
L0383
▸PrerenalnavL0384
▸Renal parenchymalnavL0385
▸Post renalnavL0386
▸• ManagementnavL0387
L0388
▸• OutcomenavL0389
L0390
▸• Other causes of AKInavL0391
L0392
▸RhabdomyolysisnavL0393
▸Contrast inducednavL0394
▸Acute tumour lysis syndromenavL0395
▸Acute Hyperuricemic nephropathynavL0396
▸![figure](slide35.png)Slide 35figure_refL0397

Other causes of AKI shown 1 of 7[L0399–L0408]

▸Rhabdomyolysis or “crush syndrome”L0399
Explain like I'm five
What
Names this section's topic: rhabdomyolysis, also called "crush syndrome."
Same condition, two names

The lecture gives two names for one entity here: rhabdomyolysis and "crush syndrome."

Explain like I'm five
What
Rhabdomyolysis and 'crush syndrome' are given as two names for the same entity: skeletal muscle injury that provokes release of intracellular myoglobin.
Where
Both names appear together in the heading line opening the 'Other causes of AKI: Rhabdomyolysis' slide.

Why this matters: A question or report using either term is asking about the same condition — treating them as two separate entities would double-count one topic.

▸skeletal muscle injury provokes the release of intracellular myoglobinL0400
Explain like I'm five
What
Muscle injury releases myoglobin — a protein normally confined inside muscle cells.
Where
Myoglobin sits inside skeletal muscle cells until the injury releases it.
Why
She states muscle injury releases myoglobin but does not say how or why that release goes on to injure the kidney — the link between rhabdomyolysis and AKI itself.
▸Causes:frameL0401
▸• trauma, compartment syndrome,L0402
Explain like I'm five
What
Two stated causes of rhabdomyolysis: trauma and compartment syndrome.
Why
She names these as causes but does not state the mechanism by which either damages muscle.
▸• excessive exertion (marathon runners),L0403
Explain like I'm five
What
A third cause: excessive physical exertion — she gives marathon runners as the example.
▸• status epilepticusL0404
Explain like I'm five
What
A fourth stated cause: status epilepticus.
▸• muscle toxins (statins, malaria and antimalarials, and snake and insect venom).L0405
L0406
Explain like I'm five
What
A fifth cause: muscle toxins — she names statins, malaria, antimalarial drugs, and snake or insect venom as examples.
Why
She lists these agents as toxic to muscle but does not state how each one damages muscle tissue to release myoglobin.
▸• Increased K, PO4, CPKL0407
Explain like I'm five
What
States three raised lab values listed here: potassium (K), phosphate (PO4), and CPK.
Why
She lists these three values as raised but does not explain why muscle breakdown raises each of them.
▸![figure](slide36.png)Slide 36figure_refL0408

Other causes of AKI shown 2 of 7[L0410–L0415]

▸• Contrast nephropathyL0410
Explain like I'm five
What
Names the complication covered next: nephropathy (kidney damage) caused by iodinated contrast dye used in imaging.
▸In patients with impaired renal function, iodinated radiological contrast media may be nephrotoxic, possibly by causing renal vasoconstriction and by exerting a direct toxic effect on renal tubules.L0411
L0412
L0413
L0414
Explain like I'm five
What
Iodinated contrast dye used in imaging can be toxic to the kidneys in some patients.
Where
The toxicity acts on the renal blood vessels and on the renal tubules.
How
Two possible routes, both stated as 'possibly': the dye constricts renal vessels, and/or it directly damages the tubules.
When
The risk is specifically in patients whose renal function is already impaired before the contrast is given.
▸![figure](slide37.png)Slide 37figure_refL0415

Other causes of AKI shown 3 of 7[L0417–L0423]

▸Tumour lysis syndromeL0417
Explain like I'm five
What
Names the next complication under discussion: tumour lysis syndrome.
▸It is a complication of the first treatment of lymphoproliferative tumoursL0418
L0419
Explain like I'm five
What
Tumour lysis syndrome is a complication that follows treatment of lymphoproliferative tumours.
When
Specifically the first treatment given for these tumours.
▸Chemotherapy (or even steroids), causing rapid death of malignant cells with the release of intracellular and membrane products, including URIC ACID, potassium and phosphate.L0420
L0421
L0422
Explain like I'm five
What
Chemotherapy, or even steroids alone, causes malignant cells to die rapidly and release their internal contents into the blood.
How
The released material specifically includes uric acid, potassium and phosphate — the substances that build up to cause the syndrome.
▸![figure](slide38.png)Slide 38figure_refL0423
slide38.png (Tumour lysis syndrome)slide38.png (Tumour lysis syndrome)

Slide repeats the row text verbatim, but highlights URIC ACID in yellow within the sentence listing released products (uric acid, potassium, phosphate).

The yellow highlight singles out uric acid as the emphasised product among the three released — a visual cue the plain text does not carry, and it foreshadows the next three slides, all on acute hyperuricaemic nephropathy specifically.

Other causes of AKI shown 4 of 7[L0425–L0432]

▸Acute hyperuricaemic nephropathyL0425
Explain like I'm five
What
Names the specific mechanism of kidney injury covered next: kidney damage from excess uric acid.
▸• It may occur prior to or after treatmentL0426
Explain like I'm five
When
Can happen either before chemotherapy is given, or after it — not confined to one window.
▸• tumour cells lyse in response to chemotherapy, large amounts of nucleoprotein are released with increased uric acid production.L0427
L0428
Explain like I'm five
What
Chemotherapy causes tumour cells to lyse (burst apart).
How
Chemotherapy bursts the tumour cells; she states that large amounts of nucleoprotein are released and that uric acid production rises. She does not name the step between them.
▸• Renal failure is due to intrarenal and extrarenal obstruction caused by deposition of uric acid crystals in the collecting ducts, pelvis and ureters.L0429
L0430
L0431
Explain like I'm five
What
Renal failure here comes from physical obstruction, not from direct toxicity to kidney tissue.
Where
Both inside the kidney (collecting ducts) and outside it (renal pelvis, ureters).
How
Uric acid crystals deposit in these structures and physically block urine flow.
Two-step mechanism: uric acid overproduction to renal failure

Tumour lysis raises uric acid production, and the excess uric acid then crystallises and blocks the urinary tract, causing renal failure.

tumour cells lyse in response to chemotherapy, large…→Renal failure is due to intrarenal and extrarenal…

Explain like I'm five
What
Tumour cell lysis releases nucleoprotein, raising uric acid production; the excess uric acid crystallises and obstructs the collecting ducts, pelvis and ureters, causing renal failure.
How
Stated as chemotherapy → cell lysis → uric acid overproduction → crystal deposition → intrarenal/extrarenal obstruction → renal failure.

Why this matters: Naming the two-step chain — overproduction then crystallisation and obstruction — is what makes prevention (lowering uric acid before it crystallises) the logical target, rather than treating the renal failure as unrelated to the tumour lysis.

▸![figure](slide39.png)Slide 39figure_refL0432

Other causes of AKI shown 5 of 7[L0434–L0439]

▸Acute hyperuricaemic nephropathyL0434
Explain like I'm five
What
Same condition as before, now covered from the diagnosis angle.
▸Diagnosis is based on the hyperuricaemia and the clinical settingL0435
L0436
Explain like I'm five
What
Diagnosis combines lab evidence (hyperuricaemia) with the clinical picture, rather than resting on either alone.
▸Ultrasound may demonstrate extrarenal obstruction due to stones but may be unremarkable.exceptionL0437
L0438
Explain like I'm five
What
Ultrasound may show extrarenal obstruction caused by stones — but it may also look unremarkable despite obstruction being present.
ExceptionRule: ultrasound may show extrarenal obstruction from stones. Exception: she states it may be unremarkable, so a normal scan does not exclude it.
▸![figure](slide40.png)Slide 40figure_refL0439

Other causes of AKI shown 6 of 7[L0441–L0448]

▸Acute hyperuricaemic nephropathyL0441
Explain like I'm five
What
Same condition again, now covered from the treatment angle.
▸Treatment:frameL0442
▸• Allopurinol prior to and throughout treatment with radiotherapy or cytotoxic drugs.L0443
L0444
Explain like I'm five
What
Allopurinol is given as prevention.
When
Started before radiotherapy or cytotoxic (chemotherapy) treatment begins, and continued throughout it.
▸• oral or parenteral fluidsL0445
Explain like I'm five
What
Fluids are given, either by mouth or intravenously, as part of treatment.
▸• Alkalinisation of urine by the administration of sodium bicarbonateL0446
L0447
Explain like I'm five
What
Urine is made more alkaline as part of treatment.
How
Achieved by giving sodium bicarbonate.
▸![figure](slide41.png)Slide 41figure_refL0448
Not in the markdown — read from the slideslide41.png (Acute hyperuricaemic nephropathy — treatment)Plain text slide; every line already appears as its own row above. Her own emphasis: Allopurinol is printed in bold italic inside its bullet, distinct from the plain surrounding sentence — she is calling out the drug name itself, not just the sub-heading.

Other causes of AKI shown 7 of 7[L0450–L0458]

▸Acute hyperuricaemic nephropathyL0450
Explain like I'm five
What
Names the condition under discussion — acute hyperuricaemic nephropathy — before the treatment bullets that follow describe how it is managed.
Where
Sits after this lecture's earlier coverage of the condition's cause and diagnosis, and after first-line allopurinol treatment; this slide is the treatment continuation.
▸Treatment ( cont.)frameL0451
▸• Febuxostat, a non-purine analogue inhibitor of xanthine oxidase, can be used if allopurinol cannot be tolerated and eGFR is more than 30 mL/min.L0452
L0453
L0454
Explain like I'm five
What
Febuxostat, a non-purine analogue drug, is one option for treating acute hyperuricaemic nephropathy.
How
It works by inhibiting xanthine oxidase — that is as far as the mechanism is stated.
When
Used specifically when allopurinol cannot be tolerated, and only if eGFR is above 30 mL/min — not a first-line choice.
▸• Rasburicase , a recombinant urate oxidaseL0455
Explain like I'm five
What
Rasburicase, a recombinant urate oxidase enzyme, is offered as a further drug option alongside febuxostat for this condition.
How
She names it a recombinant urate oxidase and does not say more — no mechanism, no dose, no timing relative to febuxostat.
▸• In severely oliguric or anuric patients, dialysis is required to lower the plasma urate.L0456
L0457
Explain like I'm five
What
Dialysis is used to bring plasma urate down directly, as a treatment route separate from the two drugs above.
Why
She ties the need for dialysis to how oliguric or anuric the patient is but does not state why reduced urine output demands this route.
When
Specifically for patients who are severely oliguric or anuric — not stated as needed for milder cases.
▸![figure](slide42.png)Slide 42figure_refL0458
Not in the markdown — read from the slideslide42.png (Acute hyperuricaemic nephropathy, treatment cont.)Plain text slide; every line already appears as its own row above. Her own emphasis: Rasburicase is printed in bold italic inside its bullet, the same treatment given to Allopurinol on the previous slide — Febuxostat in the bullet above it is left plain.

Other causes of CKD exception[L0460–L0465]

Exception · source errorHeading reads 'Other causes of CKD' inside an AKI lecture; the content beneath it is hepatorenal syndrome, a cause of AKI, not CKD.
▸Hepatorenal syndromeL0460
Explain like I'm five
What
Names the condition this slide covers: hepatorenal syndrome, a cause of acute kidney injury.
Where
Placed under this document's '## Other causes of CKD' heading, even though the content describes a cause of AKI, not CKD.
▸The renal failure observed in hepatorenal syndrome results from profound renal vasoconstriction with histologically normal kidneys patients with liver cirrhosis, portal hypertension and ascites.L0461
L0462
L0463
L0464
Explain like I'm five
What
In hepatorenal syndrome, kidney failure comes from severe constriction of the renal blood vessels, not from damage to the kidneys themselves.
Where
The kidneys are histologically normal; the problem sits in their blood supply, occurring in patients with cirrhosis, portal hypertension and ascites.
How
She states that vasoconstriction is the mechanism but does not state what in cirrhosis, portal hypertension or ascites triggers that constriction.
▸![figure](slide43.png)Slide 43figure_refL0465

Outcome[L0467–L0475]

▸Outcomes vary:L0467
Explain like I'm five
What
States plainly that AKI's outcome is not fixed; the three bullets below give the range from good to poor.
Where
Introduces the three outcome bullets that follow, each naming a different clinical scenario rather than one single prognosis.
Same dimension, three severities compared

AKI's mortality risk is not fixed: it rises with how complicated the case is, worst with ITU-level non-renal organ failure. Separately, the lecture states sepsis-related AKI carries a worse prognosis than AKI without sepsis — it is not benchmarked against the ITU figure.

uncomplicated AKI<5–10% mortalityAKI with non-renal organ failure (ITU)50–70% mortalitysepsis-related AKIworse than AKI without sepsis, no percentage given
Explain like I'm five
What
Uncomplicated AKI carries under 5–10% mortality; AKI with non-renal organ failure in the ITU carries 50–70% mortality; sepsis-related AKI is stated as worse than non-septic AKI, with no percentage given.
Why
These are two separate comparisons, not one ranked scale — the sepsis line is never benchmarked against the ITU figure.

Why this matters: Prognosis in AKI depends on context, but the source makes two separate comparisons here, not one ranked scale of three: uncomplicated AKI vs ITU-level organ failure by percentage, and sepsis-related AKI vs non-sepsis AKI with no percentage given — the sepsis line is not stated to beat the ITU figure.

▸• uncomplicated AKI carries a good prognosis, with mortality rates of less than 5–10%.L0468
L0469
Explain like I'm five
What
Uncomplicated AKI, occurring on its own, has a good outlook: under 5–10% mortality.
Why
She states this outcome as a fact and does not explain why uncomplicated AKI carries a better prognosis.
▸• AKI complicating non-renal organ system failure (in the intensive treatment unit (ITU) setting) is associated with mortality rates of 50–70%L0470
L0471
L0472
Explain like I'm five
What
AKI layered onto failure of other organs, in an ITU setting, is far more dangerous: 50–70% mortality.
Why
She uses 'associated with', not a causal claim: AKI plus non-renal organ failure in the ITU setting is associated with 50–70% mortality, above the uncomplicated case above.
▸• Sepsis-related AKI has a significantly worse prognosis than AKI in the absence of sepsis.L0473
L0474
Explain like I'm five
What
AKI occurring with sepsis carries a worse prognosis than AKI without sepsis present; no percentage is given for this group.
Why
She states sepsis worsens the prognosis but gives no mortality figure for this group and does not state why sepsis is the factor that matters.
▸![figure](slide44.png)Slide 44figure_refL0475

References[L0477–L0478]

▸• Kumar and Clark's Clinical Medicine, 10th EditionnavL0477
▸![figure](slide45.png)Slide 45figure_refL0478

Thank you[L0480–L0480]

▸![figure](slide46.png)Slide 46figure_refL0480